In recent years, China has established stem cell and regenerative medicine research as an important strategic deployment, and has given strong support to its basic research, key technologies, resource platform construction and industrial development. As a leading enterprise in the stem cell industry in Hunan Province for many years, state-owned holding listed enterprise Nanhua Bio-Medicineco.Ltd(000504) (hereinafter referred to as ” Nanhua Bio-Medicineco.Ltd(000504) “) has made a key layout in the field of stem cell regenerative medicine.
national and local support for the development of stem cell regenerative medicine
Since the 12th Five Year Plan, through the national key basic research and development plan, high-tech research and development plan and the National Natural Science Foundation of China, we have continuously strengthened the funding intensity in the field of stem cells and regenerative medicine, and have invested more than 4 billion yuan to support relevant research. “Stem cell research and organ repair” has also been listed as the first batch of key special tasks to be launched in the national key R & D plan of the 14th five year plan.
Stem cell regenerative medicine is in line with the economic development strategy of “three high and four new” in Hunan Province, and has important scientific significance and broad application prospects. The development plan of health industry in Hunan Province (2016-2020), the 13th five year plan for scientific and technological innovation in Hunan Province and the 14th five year plan for the construction of health Hunan have all made arrangements for the development of stem cell technology and the promotion of major drug industrialization. In January 2022, during the two sessions of Hunan Province, CPPCC members Wu Jinming, Kong Heping, Chen Hongzhong and Zheng Ansheng jointly made suggestions to support the development of Hunan stem cell and regenerative medicine industry cluster.
build an industry university research base for “stem cell regenerative medicine and reproductive health”
In 2021, Hunan Boai Kangmin stem cell tissue engineering Co., Ltd., a wholly-owned subsidiary of Nanhua Bio-Medicineco.Ltd(000504) , signed an agreement with Changsha maternal and child health hospital and Hunan Normal University to jointly build an industry university research cooperation demonstration base of “stem cell regenerative medicine and reproductive health”. On January 10, 2022, He Jun, vice president of Changsha maternal and child health hospital, Hu Xiang, associate professor of Hunan Normal University, and Wu Le, general manager of Hunan Boai Kangmin stem cell tissue engineering Co., Ltd., unveiled the industry university research cooperation demonstration base of “stem cell regenerative medicine and reproductive health”, and officially started the construction.
“Stem cell regenerative medicine and reproductive health” industry university research cooperation demonstration base is based on the advanced stem cell regenerative medicine research technology platform and achievements of Hunan Normal University and the mature stem cell drug R & D and industrialization platform of Hunan Boai Kangmin stem cell tissue engineering Co., Ltd, Integrating the advantageous resources and clinical technology of Changsha maternal and child health hospital in the field of reproductive health, through the “small organization, large network” industry university research cooperation mode, and making full use of the “973” and “863” research results, we will speed up the engineering and industrialization process of R & D achievements of stem cell regenerative medicine.
stem cell regenerative medicine and reproductive health
Reproductive health is related to population health, and surveys in recent years show that the situation of female reproductive health in China is not optimistic. According to statistics, the number of infertility patients in China is over 50 million, of which 20%-40% is caused by endometrial injury. Infertility caused by premature ovarian failure accounts for 15%-25%. The number and incidence rate of infertility are increasing and younger. Under the policy of “three children in full liberalization”, the number of pregnant women and the number of pregnant women with scar uterus is increasing. The incidence rate of placenta implantation, preeclampsia, gestational diabetes and other pregnancy complications also increases.
Clinical research shows that stem cells have the potential to regenerate a variety of cells, can comprehensively repair the damaged tissues of human body at the cellular level, and also have a strong immunomodulatory effect. They can reduce the inflammatory response, improve the pathological microenvironment, provide a new entry point for the clinical treatment of refractory diseases in women’s gynecology and obstetrics, and are of great significance to improve and protect women’s reproductive health. So far, in the field of reproductive health, 13 stem cells have been applied to clinical research projects related to ovarian dysfunction and endometrial injury in China, which have been filed by the health commission. Most of them use umbilical cord derived mesenchymal stem cells.
The industry university research cooperation demonstration base of “stem cell regenerative medicine and reproductive health” will mainly focus on stem cell regenerative medicine technology to carry out relevant scientific research projects in the field of maternity and reproductive health, such as basic and clinical application research on stem cells to improve ovarian function and repair endometrial damage, Develop a series of stem cell by-products combined with biomaterials for postpartum repair; Another research direction is the establishment of standardized obstetric biological sample database. Through the establishment of standardized processes and standardized management of obstetric sample collection, quality control and information, early warning, early screening, diagnosis and treatment of pregnancy and genetic diseases can be realized.
Nanhua Bio-Medicineco.Ltd(000504) four scientific research transformation platforms
At present, the scientific research transformation platform of Nanhua Bio-Medicineco.Ltd(000504) has formed a four legged development trend. In addition to the industry university research cooperation demonstration base of “stem cell regenerative medicine and reproductive health”, it also has the national stem cell transformation resource bank, Hunan clinical research center, the national local joint engineering laboratory for the creation of animal polypeptide drugs and Hunan Nanhua Bio-Medicineco.Ltd(000504) Institute of medicine.
Nanhua Bio-Medicineco.Ltd(000504) will give full play to the advantageous background of the listed companies on the main board of state-owned assets, improve the construction of scientific research platform, upgrade the strength of scientific research technology, strengthen the transformation of scientific and technological achievements, realize the combination of platform and project, seize the commanding height of biomedical R & D and production, and contribute to the in-depth implementation of the “three high and four new” strategy, Inject new impetus into the technological innovation of national stem cell regenerative medicine.
